Artera Announces Two Presentations at ASTRO 2024 Validating its MMAI Platform to Inform Treatment Decisions for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC)
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present [...]
Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, will present three [...]
New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the valid [...]
ArteraAI and Movember Announce New Relationship
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today anno [...]
ArteraAI Included in the 2024 NCCN Guidelines® for Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
ArteraAI Receives Medicare Payment Rate for the ArteraAI Prostate Cancer Test
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
ArteraAI Validates its Prognostic Model in Advanced Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announces [...]
ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today t [...]